BioSpace News Archive

Revelation Biosciences Inc. (Revelation), announced today that it has engaged MedWorld Advisors to optimize the value of Revelation’s diagnostic tool, REVID™.

Lexaria Bioscience Corp. has commenced an important new study exploring whether DehydraTECH TM -CBD evidences superior ability to inhibit seizure activity

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type A meeting to medac for treosulfan, a bifunctional alkylating agent developed for use as part of a conditioning treatment for patients prior to undergoing allogeneic hematopoietic stem cell transplantation.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that clinical data on its therapeutic candidates Nyxol® and APX3330 will be featured in poster sessions as presentations at the upcoming American Academy of Ophthalmology (AAO) 2021 annual meeting to take place in New Orleans, November 12 – 15.

Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”)

Horizon Therapeutics plc announced presentations on results from a new survey of practicing rheumatologists suggesting the presence of negative gout stigma surrounding causality and management of gout.